Effects of subanesthetic repeated esketamine infusions on memory function and NGF in patients with depression: An open-label study DOI

Qiongyao Yang,

Yitan Yao, Xiaoping Yuan

et al.

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders DOI Open Access
Hana Shafique,

Julie Demers,

Julia Biesiada

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6804 - 6804

Published: June 20, 2024

NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative epilepsy, traumatic brain injury, substance abuse disorder (SUD), major depressive (MDD). (S)-ketamine was the first of a novel class antidepressants, rapid-acting to be approved medical use. The stereoisomer, (R)-ketamine (arketamine), is currently under development treatment-resistant depression (TRD). compound has demonstrated efficacy multiple animal models. Two clinical studies disclosed TRD bipolar depression. A study by drug sponsor recently failed reach priori endpoints but post hoc analysis revealed efficacy. value supported experimental data humans rodents, showing that it less sedating, does not produce marked psychotomimetic or dissociative effects, than (S)-ketamine, produces models range disorders. mechanisms action antidepressant effects are hypothesized due antagonism and/or non-NMDA mechanisms. We suggest further experimentation with will create improved medicines some disorders underserved current medications.

Language: Английский

Citations

11
Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions DOI Creative Commons
Kenji Hashimoto, Mingming Zhao, Tingting Zhu

et al.

Journal of Anesthesia and Translational Medicine, Journal Year: 2024, Volume and Issue: 3(3), P. 65 - 75

Published: July 11, 2024

Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, similarly employed for anesthesia analgesia. The anesthetic effects of ketamine esketamine arise from their antagonism the N-methyl-D-aspartate receptor (NMDAR). In field psychiatry, rapid-acting antidepressant properties severe depression have generated significant interest, resulting its increased off-label usage United States (U.S.). 2019, nasal spray received approval use U.S. Europe. However, concerns emerged regarding potential adverse effects, including long-term efficacy, addiction risks, suicide risk clinical settings. contrast, arketamine, (R)-enantiomer ketamine, exhibits superior longer-lasting rodent models depression, with fewer side compared to esketamine. Nevertheless, research on efficacy safety arketamine patients remains limited. This article provides concise exploration historical two enantiomers while also delving into future directions application these fields.

Language: Английский

Citations

11
Activation of Sirt6 by icariside Ⅱ alleviates depressive behaviors in mice with poststroke depression by modulating microbiota-gut-brain axis DOI Creative Commons
Jianmei Gao, Y.L. He, Feng Shi

et al.

Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Sirt6-mediated gut microbiota plays a vital role in poststroke depression (PSD). Icariside Ⅱ (ICS Ⅱ) is naturally-occurring neuroprotectant with Sirt6 induction potency. However, it unknown whether ICS protects against PSD through modulation of microbiota. This study aimed to reveal the effect and potential mechanisms on PSD, microbiota-gut-brain axis was investigated. Using middle cerebral artery occlusion (MCAO) chronic unpredictable mild stress (CUMS) establish post-stroke (PSD) mice, we assessed anti-depressant effects via behavioral tests, immunohistochemistry, western blot. Transcriptome profiling, molecular docking, surface plasmon resonance were used identify key targets. 16S rDNA genomic-derived taxonomic profiling fecal transplantation (FMT) conducted figure out mechanistic short-chain fatty acids (SCFAs). ameliorated depressive-like behaviors mice as evidenced by sucrose preference test, forced swimming test tail suspension test. restored mitochondrial function, reduced oxidative damage pro-inflammatory cytokines both brain intestine regulation Sirt6/NF-κB pathway. significantly increased abundance (such asAkkermansia Ligilactobacillus), enhanced SCFAs concentrations, repaired intestinal barrier integrity upreglated tight junction protein expression. FMT from II-treated replicated these benefits, confirming microbiota's role. Mechanistically, directly bound its activity. Ⅱ-mediated neuroprotection neutralized or hydrogen peroxide-induced enteric glial cells when absent. Our findings expand pharmacological properties II demonstrating ability ameliorate axis. Ⅱ, novel activator, could be translated into an alternative microbiota-targeted avenue for coping PSD.

Language: Английский

Citations

1
Astragaloside IV mediates radiation-induced neuronal damage through activation of BDNF-TrkB signaling DOI
Xin Liu,

Yanping Ding,

Chenxin Jiang

et al.

Phytomedicine, Journal Year: 2024, Volume and Issue: 132, P. 155803 - 155803

Published: June 12, 2024

Language: Английский

Citations

5
Huanglian Wendan Decoction Improves Insomnia in Rats by Regulating BDNF/TrkB Signaling Pathway Through Gut Microbiota-Mediated SCFAs and Affecting Microglia Polarization DOI
Min Shi, Jie Yang, Ying Liu

et al.

Molecular Neurobiology, Journal Year: 2024, Volume and Issue: unknown

Published: July 2, 2024

Language: Английский

Citations

4
Esketamine-mediated alleviation of electroconvulsive shock-induced memory impairment is associated with the regulation of mGluR5 in depressive-like rats DOI Creative Commons
Yiwei Shen, Ran Wei, Dawei Liu

et al.

Pharmacology Biochemistry and Behavior, Journal Year: 2025, Volume and Issue: 248, P. 173955 - 173955

Published: Jan. 4, 2025

Language: Английский

Citations

0
Repeated administration of esketamine ameliorates mechanical allodynia in mice with chemotherapy-induced peripheral neuropathy: A role of gut microbiota and metabolites DOI

Wei-Wei Luan,

Hanwen Gu,

Di Qiu

et al.

Neurochemistry International, Journal Year: 2025, Volume and Issue: 185, P. 105961 - 105961

Published: March 5, 2025

Language: Английский

Citations

0
The effect and mechanism of low-dose esketamine in neuropathic pain-related depression-like behavior in rats DOI
L. P. Wang, Shuwu Zhao, Jiali Shao

et al.

Brain Research, Journal Year: 2024, Volume and Issue: 1843, P. 149117 - 149117

Published: July 6, 2024

Language: Английский

Citations

3
Effects of subanesthetic repeated esketamine infusions on memory function and NGF in patients with depression: An open-label study DOI

Qiongyao Yang,

Yitan Yao, Xiaoping Yuan

et al.

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

0